​

Quoin Pharmaceuticals (QNRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

QNRX Stock Rating

Quoin Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

QNRX Price Target Upside V Benchmarks

TypeNameUpside
StockQuoin Pharmaceuticals-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.48$6.48$6.48
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2611---2
Mar, 2611---2
Feb, 2611---2
Jan, 2611---2
Dec, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 27, 2026Alliance Global PartnersBuyBuyhold
Mar 15, 2024Maxim GroupBuyBuyhold

Financial Forecast

EPS Forecast

$-15K $-11K $-7K $-3K $1K $5K Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-337.47$-66.85$-14.80K---
Avg Forecast$-9.47$-2.08$-1.48$-0.05$1.15$1.34
High Forecast$-8.55$-2.08$-1.48$-0.05$1.15$1.34
Low Forecast$-10.39$-2.08$-1.48$-0.05$1.15$1.34
Surprise %3463.57%3113.94%999647.30%---

Revenue Forecast

$10M $21M $32M $43M $54M $65M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$15.58M$14.39M$48.51M$60.97M
High Forecast--$15.58M$14.39M$48.51M$60.97M
Low Forecast--$15.58M$14.39M$48.51M$60.97M
Surprise %------

Net Income Forecast

$-20B $-15B $-10B $-5B $0 $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.69M$-8.96M$-15.80B---
Avg Forecast$-8.69M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
High Forecast$-7.70M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
Low Forecast$-9.36M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
Surprise %-378.18%1187659.98%---

QNRX Forecast FAQ

Is Quoin Pharmaceuticals stock a buy?

Quoin Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Quoin Pharmaceuticals is a favorable investment for most analysts.

What is Quoin Pharmaceuticals's price target?

Quoin Pharmaceuticals's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $6.48.

How does Quoin Pharmaceuticals stock forecast compare to its benchmarks?

Quoin Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Quoin Pharmaceuticals over the past three months?

  • April 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Quoin Pharmaceuticals’s EPS forecast?

Quoin Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.05, marking a -100.00% decrease from the reported $-14.796K in 2025. Estimates for the following years are $1.15 in 2027, and $1.34 in 2028.

What is Quoin Pharmaceuticals’s revenue forecast?

Quoin Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $14.39M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $48.51M, and $60.97M for 2028.

What is Quoin Pharmaceuticals’s net income forecast?

Quoin Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-45.055K, representing a -100.00% decrease from the reported $-15.805B in 2025. Projections indicate $1.04M in 2027, and $1.21M in 2028.